Last updated: September 28, 2026
DALVANCE, the U.S. brand for dalbavancin, is a long-acting lipoglycopeptide antibiotic approved for acute bacterial skin and skin-structure infections. Its commercial value is based on outpatient convenience: treatment can be completed with one 1,500-mg infusion or two infusions administered one week apart. The product has a differentiated delivery profile but competes against low-cost generic antibiotics and hospital protocols built around vancomycin.
Dalbavancin revenue is not separately reported by AbbVie, which acquired the product through its 2019 acquisition of Allergan. Public filings therefore do not provide a verified product-level revenue trajectory. The commercial outlook depends more on hospital adoption, outpatient parenteral antibiotic therapy, emergency-department utilization, and reimbursement than on expansion into a broad range of infectious-disease indications.
What is DALVANCE and how is it used?
DALVANCE contains dalbavancin hydrochloride, a semisynthetic lipoglycopeptide that inhibits bacterial cell-wall synthesis. The FDA approved it on May 23, 2014, for the treatment of acute bacterial skin and skin-structure infections caused by susceptible Gram-positive organisms, including methicillin-resistant Staphylococcus aureus.[1]
The principal dosing options are:
| Regimen |
Use |
| 1,500 mg intravenously once |
Single-dose treatment |
| 1,000 mg intravenously, followed by 500 mg one week later |
Two-dose treatment |
| Pediatric weight-based dosing |
Approved by FDA in 2022 for patients from birth to less than 18 years old |
Dalbavancin has a terminal half-life of approximately 14 days. This pharmacokinetic profile allows treatment without daily infusion or a prolonged indwelling venous catheter.[1]
The label does not establish DALVANCE as a general treatment for all serious Gram-positive infections. Use outside the approved acute bacterial skin and skin-structure infection indication is common in clinical practice but remains off-label.
What drives DALVANCE market demand?
The main commercial drivers are treatment convenience, hospital capacity, and avoidance of outpatient intravenous therapy complications.
Outpatient and emergency-department use
Dalbavancin can be administered in an emergency department, hospital outpatient department, infusion center, or selected physician-office settings. Hospitals may use it for patients who would otherwise require:
- Daily vancomycin administration
- A peripherally inserted central catheter
- Home-health nursing
- Therapeutic drug monitoring
- Repeated laboratory testing
- Extended inpatient observation
The economic value is strongest when dalbavancin prevents an admission or enables earlier discharge. Its acquisition price is substantially higher than that of generic vancomycin, so a hospital’s decision depends on the total episode cost rather than the drug price alone.
Antimicrobial stewardship
DALVANCE is active against important Gram-positive pathogens, including MRSA. Its long half-life can support adherence when daily outpatient therapy is impractical. The same long exposure creates stewardship concerns because adverse events or inappropriate treatment cannot be rapidly reversed after administration.
Hospitals generally reserve use for selected patients rather than treating it as a universal first-line replacement for vancomycin or beta-lactam therapy.
Patient selection
Commercial use is most attractive when the patient has:
- A confirmed or strongly suspected Gram-positive infection
- Difficulty receiving daily infusions
- Unstable housing or limited access to follow-up care
- A high risk of leaving treatment before completion
- A need for rapid discharge
- A clinical reason to avoid a central line
Renal impairment also affects dosing. The prescribing information provides dose adjustments for certain patients with substantially reduced renal function who are not receiving regular hemodialysis.[1]
How has the DALVANCE financial trajectory developed?
The product’s financial history has been shaped by ownership changes rather than transparent standalone revenue reporting.
| Date |
Event |
Commercial significance |
| May 23, 2014 |
FDA approval of DALVANCE |
U.S. commercial launch of dalbavancin for acute bacterial skin and skin-structure infections |
| October 2014 |
Actavis agreed to acquire Durata Therapeutics |
Actavis paid approximately $675 million in upfront consideration, with additional contingent consideration reported in the transaction announcement |
| 2015 |
Actavis completed its combination with Allergan |
DALVANCE became part of the Allergan infectious-disease portfolio |
| 2019 |
AbbVie announced acquisition of Allergan |
AbbVie obtained commercial control of DALVANCE |
| 2022 |
FDA pediatric approval |
Expanded the labeled population without creating a new adult indication |
| 2024 |
AbbVie continued to report at portfolio level |
Product-level DALVANCE revenue was not separately disclosed in public annual-report revenue tables |
The 2014 acquisition price reflected the value of an approved hospital antibiotic with a differentiated dosing profile, not a product with the sales scale of a mass-market chronic therapy. Financial returns depend on sustained premium pricing, favorable site-of-care economics, and expansion of use within targeted patient populations.
AbbVie’s public reporting groups many products into broader therapeutic or operating categories. It does not provide a reliable, standalone annual revenue series for DALVANCE in its regular financial statements.[2] As a result, claims about precise annual sales, compound annual growth, or current market share require proprietary prescription, hospital purchasing, or claims datasets.
How does DALVANCE compare with competing antibiotics?
DALVANCE competes with both branded long-acting antibiotics and inexpensive generic alternatives.
| Product |
Active ingredient |
Dosing profile |
Main commercial advantage |
| DALVANCE |
Dalbavancin |
One dose or two weekly doses |
Long duration and outpatient convenience |
| ORBACTIV |
Oritavancin |
Single intravenous dose |
One-time treatment option |
| VANCOCIN and generics |
Vancomycin |
Usually daily or more frequent dosing |
Low drug cost and broad hospital familiarity |
| Zyvox and generic linezolid |
Linezolid |
Oral or intravenous |
Oral availability and generic pricing |
| SIVEXTRO |
Tedizolid |
Once daily for six days |
Short course and once-daily administration |
| Cubicin and generic daptomycin |
Daptomycin |
Daily intravenous dosing |
Established use in serious Gram-positive infections |
| Cefazolin and other beta-lactams |
Various |
Usually repeated dosing |
Low cost and strong role in susceptible infections |
DALVANCE’s closest branded comparator is ORBACTIV. Both products seek to reduce treatment burden through long-acting intravenous dosing. ORBACTIV has a single-dose regimen but faces similar hospital-budget constraints and has not displaced generic vancomycin broadly.
Generic linezolid is a major price competitor because it offers oral treatment for clinically appropriate patients. Vancomycin remains difficult to displace where inpatient monitoring is already available or where its low acquisition price dominates the hospital decision.
What is the FDA regulatory status of DALVANCE?
DALVANCE is FDA-approved for adults and pediatric patients with acute bacterial skin and skin-structure infections caused by designated susceptible Gram-positive organisms.[1]
The product’s main regulatory milestones are:
- New drug application approval: May 23, 2014
- Adult indication: acute bacterial skin and skin-structure infections
- Adult regimens: single-dose and two-dose intravenous treatment
- Pediatric expansion: FDA approval in 2022
- Regulatory category: small-molecule antibacterial drug
- Biosimilar pathway: not applicable
The product does not have biologic exclusivity. Any future competitive product would proceed through the small-molecule generic drug pathway rather than the biosimilar pathway.
The original five-year new chemical entity exclusivity period would have expired in 2019, absent any applicable extension. Pediatric exclusivity can extend certain FDA protections by six months when statutory requirements are met, but it does not create a permanent barrier to generic competition.
What patents protect DALVANCE?
Protection for DALVANCE has historically involved patents covering dalbavancin chemistry, glycopeptide derivatives, pharmaceutical compositions, and manufacturing methods. Patent scope and enforceability must be evaluated by claim, jurisdiction, and Orange Book listing rather than by the product name alone.
The commercial patent questions are:
- Whether any unexpired U.S. patent is listed for DALVANCE in the FDA Orange Book.
- Whether a listed patent covers the active ingredient, formulation, dosage regimen, or only a manufacturing process.
- Whether an ANDA applicant has filed a Paragraph IV certification.
- Whether any patent term extension or pediatric extension applies.
- Whether non-U.S. patents remain enforceable in markets where Xydalba is sold.
A patent on a manufacturing process may be less effective against generic entry than a patent covering the active ingredient or a core pharmaceutical composition. Conversely, a generic applicant may avoid a method-of-use patent by carving out the protected indication from its label.
Because AbbVie does not publish a standalone DALVANCE patent schedule in its annual reports, the Orange Book and relevant patent registers are the controlling sources for current expiry and listing status.[3]
When does DALVANCE lose exclusivity?
The key U.S. regulatory exclusivity period has already expired. DALVANCE’s five-year new chemical entity exclusivity ran from the 2014 approval date and generally ended in 2019. The practical date for generic entry depends on any remaining listed patents, FDA review timing, Paragraph IV litigation, and whether an ANDA applicant obtains 180-day first-filer exclusivity.
A simplified exclusivity timeline is:
| Protection |
Approximate status |
| Five-year new chemical entity exclusivity |
Expired in 2019 |
| Pediatric exclusivity |
Potential six-month extension after qualifying pediatric work |
| Orange Book patents |
Must be confirmed against the current FDA listing |
| Manufacturing patents |
May remain relevant even when regulatory exclusivity has ended |
| Data exclusivity outside the U.S. |
Varies by country and regulatory framework |
No biosimilar exclusivity applies. The principal future risk is therefore conventional generic entry.
Are there Paragraph IV challenges or DALVANCE patent lawsuits?
A Paragraph IV challenge would be the most direct route to early generic competition. It would require an ANDA applicant to certify that a listed patent is invalid, unenforceable, or will not be infringed.
Public AbbVie filings do not identify DALVANCE as a major standalone patent-litigation asset or disclose a material ongoing litigation matter that would permit a definitive generic-entry forecast.[2] The absence of a prominently disclosed dispute does not establish that no ANDA has been filed or that no patent challenge exists. FDA approval records and federal court dockets control that analysis.
For investors, the relevant indicators are:
- An ANDA filing with a Paragraph IV certification
- A 45-day patent-infringement complaint by the patent holder
- A 30-month FDA approval stay
- A settlement agreement providing a licensed generic-entry date
- A first-filer 180-day exclusivity period
- A court finding invalidity, non-infringement, or patent enforceability
What generic launch scenarios exist for DALVANCE?
The most likely commercial scenarios are:
Scenario 1: Delayed generic entry
If core patents remain enforceable, generic entry may be delayed until the relevant expiry date or a settlement date. DALVANCE would retain premium pricing but face continuing payer pressure.
Scenario 2: At-risk launch
A generic applicant could launch before final patent resolution after a favorable court ruling, a settlement, or a business decision to accept litigation risk. This would create rapid price erosion and inventory pressure.
Scenario 3: Limited generic substitution
Even after approval, generic uptake could be slower than for oral antibiotics because DALVANCE requires intravenous administration, specialized handling, hospital formulary approval, and clinical selection. A generic may initially compete through hospital contracts rather than retail pharmacy substitution.
Scenario 4: Therapeutic displacement without generic entry
Hospitals may reduce DALVANCE use through expanded oral therapy, outpatient vancomycin programs, long-acting oritavancin, or lower-cost intravenous options. This can reduce revenue before patent expiry.
How strong is the DALVANCE commercial and patent estate?
The commercial estate is differentiated but narrow.
Strengths include:
- Long half-life
- Single-dose and weekly-dose treatment options
- Strong fit with outpatient care
- Utility in adherence-challenged populations
- No biosimilar pathway
- Potential hospital savings when admission or home infusion is avoided
Weaknesses include:
- High acquisition cost
- Narrow labeled indication
- Competition from generic vancomycin and linezolid
- Limited ability to reverse exposure after administration
- Dependence on hospital protocols and reimbursement
- Lack of publicly disclosed product-level revenue
- Potential vulnerability to generic or therapeutic substitution
The patent estate is less important than it was during launch because the original regulatory exclusivity has expired. Current value depends on the scope and remaining life of any Orange Book-listed patents, manufacturing patents, and enforceable method-of-use claims.
What licensing and commercial partnerships affect DALVANCE?
DALVANCE originated with Durata Therapeutics and moved to Actavis, then Allergan, and finally AbbVie. The 2014 Actavis-Durata transaction transferred commercial control of the asset to Actavis for approximately $675 million in upfront consideration, subject to contingent payments.[4]
Outside the United States, dalbavancin has been marketed as XYDALBA under different commercial arrangements. Geographic rights and distributors have changed over time, so U.S. ownership should not be assumed to describe every market.
The product’s geographic commercial value is therefore fragmented:
| Region |
Brand or pathway |
Key issue |
| United States |
DALVANCE |
AbbVie-controlled commercial asset; FDA and Orange Book status apply |
| European markets |
XYDALBA |
Local authorization, pricing, and license arrangements vary |
| Other markets |
Country-specific |
Distribution and patent status require local review |
What revenue exposure does AbbVie have to DALVANCE?
AbbVie’s direct revenue exposure is likely modest relative to its major immunology, oncology, aesthetics, and neuroscience products. The company does not separately disclose DALVANCE sales in a manner that supports a verified percentage of total revenue.[2]
The principal financial risks are:
- Revenue erosion from generic entry
- Hospital formulary restrictions
- Declining reimbursement for outpatient infusion
- Lower utilization if oral therapy becomes more practical
- Competitive pricing from ORBACTIV and generic intravenous antibiotics
- Limited expansion beyond skin and skin-structure infections
The main upside is increased use in outpatient and emergency-care pathways where one infusion can replace several days of hospital or home-based treatment. That upside is constrained by the product’s price and by the absence of broad FDA-approved indications.
Key Takeaways
- DALVANCE is a long-acting intravenous dalbavancin product approved in 2014 for acute bacterial skin and skin-structure infections.
- Its commercial differentiation is treatment completion with one dose or two weekly doses.
- The product competes with generic vancomycin, linezolid, daptomycin, cefazolin, and branded ORBACTIV.
- AbbVie does not separately report DALVANCE revenue, preventing a verified standalone sales-growth calculation from public filings.
- The original five-year new chemical entity exclusivity expired in 2019.
- Generic entry depends on current Orange Book listings, patent expiry, Paragraph IV activity, litigation, and settlement terms.
- Biosimilar risk does not apply because dalbavancin is a small-molecule antibiotic.
- The strongest commercial use case is avoiding hospitalization, prolonged home infusion, or adherence failure.
- The main financial risk is therapeutic and generic substitution in a price-sensitive hospital market.
FAQs About DALVANCE Market and Patent Outlook
Is DALVANCE still under patent protection?
The answer depends on current Orange Book listings and any enforceable manufacturing or method-of-use patents. The original five-year FDA exclusivity expired in 2019.
Is there a generic version of dalbavancin?
A generic product requires FDA approval through the ANDA pathway. Generic availability depends on patent certifications, litigation, regulatory review, and commercial launch decisions.
Does DALVANCE have biosimilar competition?
No. Dalbavancin is a small-molecule drug, so any follow-on product would be a generic, not a biosimilar.
Why is DALVANCE expensive compared with vancomycin?
DALVANCE pricing reflects the value attributed to long duration, reduced administration frequency, outpatient treatment, and potential avoidance of hospitalization or home-infusion costs.
What could increase DALVANCE sales?
Higher emergency-department use, broader hospital adoption of outpatient antibiotic pathways, improved reimbursement, and increased treatment of patients unable to complete daily therapy could support sales growth.
References
- U.S. Food and Drug Administration. (2024). Dalvance (dalbavancin) prescribing information.
- AbbVie Inc. (2024). 2023 annual report.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Actavis plc. (2014, October 29). Actavis to acquire Durata Therapeutics for approximately $675 million plus contingent consideration.
